Amyloidosis - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 157
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AEE243D42A6EN
Leaflet:

Download PDF Leaflet

Amyloidosis - Pipeline Review, H2 2017
Amyloidosis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Amyloidosis - Overview
Amyloidosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Amyloidosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Amyloidosis - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals Inc
Amgen Inc
Arcturus Therapeutics Inc
Bsim2
Celgene Corp
GlaxoSmithKline Plc
Ionis Pharmaceuticals Inc
Johnson & Johnson
Millennium Pharmaceuticals Inc
Neurimmune Holding AG
Novartis AG
Oncopeptides AB
Pfizer Inc
Prothena Corp Plc
R Pharm
Regeneron Pharmaceuticals Inc
SOM Biotech SL
Spectrum Pharmaceuticals Inc
Amyloidosis - Drug Profiles
AG-10 - Drug Profile
ALN-ANG - Drug Profile
ALN-TTRsc02 - Drug Profile
CAEL-101 - Drug Profile
canakinumab - Drug Profile
carfilzomib - Drug Profile
CLR-01 - Drug Profile
daratumumab - Drug Profile
dezamizumab - Drug Profile
dezamizumab + GSK-2315698 - Drug Profile
doxycycline hyclate - Drug Profile
EDE-1307 - Drug Profile
GSK-2315698 - Drug Profile
GSK-3039294 - Drug Profile
inotersen sodium - Drug Profile
ixazomib citrate - Drug Profile
LUNAR-TTR - Drug Profile
melphalan - Drug Profile
melphalan flufenamide - Drug Profile
Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
NEOD-001 - Drug Profile
NI-301 - Drug Profile
NPT-289 - Drug Profile
Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
patisiran - Drug Profile
pomalidomide - Drug Profile
PRX-004 - Drug Profile
RPH-104 - Drug Profile
Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile
Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile
Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
tafamidis meglumine - Drug Profile
tolcapone - Drug Profile
Amyloidosis - Dormant Projects
Amyloidosis - Discontinued Products
Amyloidosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Amyloidosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Amgen Inc, H2 2017
Amyloidosis - Pipeline by Arcturus Therapeutics Inc, H2 2017
Amyloidosis - Pipeline by Bsim2, H2 2017
Amyloidosis - Pipeline by Celgene Corp, H2 2017
Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2017
Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Johnson & Johnson, H2 2017
Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2017
Amyloidosis - Pipeline by Novartis AG, H2 2017
Amyloidosis - Pipeline by Oncopeptides AB, H2 2017
Amyloidosis - Pipeline by Pfizer Inc, H2 2017
Amyloidosis - Pipeline by Prothena Corp Plc, H2 2017
Amyloidosis - Pipeline by R Pharm, H2 2017
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Amyloidosis - Pipeline by SOM Biotech SL, H2 2017
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Amyloidosis - Dormant Projects, H2 2017
Amyloidosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Amyloidosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Amyloidosis - Pipeline Review, H1 2017 US$ 2,000.00 Feb, 2017 · 160 pages
Stroke - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 519 pages
DBV Technologies S.A. - Product Pipeline Review - 2015 US$ 1,500.00 Apr, 2015 · 35 pages

Ask Your Question

Amyloidosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: